[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"news-aggregator-equities-analysts-offer-predic330195948d-9033-7f06-9dad-3424ee361cfe":3},{"id":4,"timestamp":5,"title":6,"content":7,"link":8,"preview":9,"tags":10,"predictedTags":11,"showTags":12,"source":13,"reactions":14,"selfReactions":15,"logo":16,"sourceId":17,"sourceUserId":18,"asset":19,"tagsCategories":20,"totalComments":21,"lang":22,"unique_views_count":23,"enrichStatus":19},"equities-analysts-offer-predic330195948d-9033-7f06-9dad-3424ee361cfe","1741952652000","Equities Analysts Offer Predictions for ZVRA FY2029 Earnings","Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - Stock analysts at  Roth Capital lowered their FY2029 earnings estimates for Zevra Therapeutics  in a report issued on  Tuesday, March 11th. Roth Capital analyst J. Aschoff now anticipates that the company will post earnings per share of $2.05 fo","https://www.marketbeat.com/instant-alerts/equities-analysts-offer-predictions-for-zvra-fy2029-earnings-2025-03-13/","https://www.marketbeat.com/images/marketbeat-logo-1200-1200.jpg?v=1","[]","[\"\",\"-\"]","[{\"name\":\"\",\"logo\":\"https://toscalepublic.s3.eu-west-2.amazonaws.com/images/blockchains/.png\"},{\"name\":\"-\",\"logo\":\"https://toscalepublic.s3.eu-west-2.amazonaws.com/images/protocols/-.png\"}]","33",[],[],"https://toscalepublic.s3.eu-west-2.amazonaws.com/images/news-feeds/sources/market-beat.png","Market Beat",null,"","[\"Other\"]","0","EN","3"]